CLTX CAR T data shows regional control of tumour recurrence
Filed with ASX · · 4 pages · English
• CLTX CAR T clinical data highlighted in Keynote presentation on November 20 • 75% disease control rate seen at lowest dose level with up to 8 weeks of durability • Tumour recurrence prevented at sites where CLTX CAR T cells were infused while tumour recurrence occurred at sites without CLTX CAR T cell infusion • CLTX CAR T was generally well tolerated with no dose limiting toxicities and no obse
Chimeric Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Chimeric Therapeutics
- CLTX CAR t presents positive initial phase 1 clinical data
- First milestone on path to CDH17 CAR t clinical trial
- European patent granted for CLTX technology used in CHM 1101
- Partnership with OncoBay Clinical to advance CHM 1101
- Preliminary Final Report
Later from Chimeric Therapeutics
- Transformative Portfolio Expansion Presentation
- Chimeric receives US patent covering CLTX CAR technology
- Sponsored Research Agreement with University of Pennsylvania
- Encouraging data from 2nd dose cohort in CLTX CAR T trial
- Entitlement Offer to raise approximately $18.1 million
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics